ProSomnus, a producer of patientpreferred medical devices for the treatment of obstructive sleep apnea, agreed to go public via a SPAC merger with Lakeshore Acquisition I, a special purpose acquisition company. in a $168m deal. PIPE investors include Cohanzick Management and CrossingBridge Advisors. “Having treated over 150k patients and received overwhelmingly positive feedback, we believe ProSomnus has the potential to drastically help people who are suffering from obstructive sleep apnea. Historically, penetration of the obstructive sleep apnea treatment market has been constrained by the invasiveness and ineffectiveness of predicate therapies, but we believe that our patient-preferred sleep apnea therapy and capital from the public markets can help us reach millions of patients worldwide,” Len Liptak, ProSomnus Co-Founder and CEO. On December 2, 2022, Lakeshore Acquisition I shareholders approved business combination with ProSomnus.